Craniopharyngioma
Jump to navigation
Jump to search
| Section editor | |
|---|---|
 |
Seema Nagpal, MD Stanford University Palo Alto, CA, USA |
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not currently have guidelines at this granular level; please go to the Central Nervous System Cancers category page.
All lines of therapy
Cobimetinib & Vemurafenib
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Brastianos et al. 2023 (Alliance A071601) | 2018-02-20 to 2020-03-31 | Phase 2 |
Eligibility criteria
- Histology: Papillary
Biomarker eligibility criteria
- BRAF mutation
Targeted therapy
- Cobimetinib (Cotellic) 60 mg PO once per day on days 1 to 21
- Vemurafenib (Zelboraf) 960 mg PO twice per day on days 1 to 28
28-day cycles
References
- Alliance A071601: Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. N Engl J Med. 2023 Jul 13;389(2):118-126. link to original article contains dosing details in manuscript PubMed NCT03224767